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Phenethyl Isothiocyanate, a Dual Activator of Transcription
Factors NRF2 and HSF1
Sharadha Dayalan Naidu, Takafumi Suzuki, Masayuki Yamamoto, Jed W. Fahey,
and Albena T. Dinkova-Kostova*
Cruciferous vegetables are rich sources of glucosinolates which are the
biogenic precursor molecules of isothiocyanates (ITCs). The relationship
between the consumption of cruciferous vegetables and chemoprotection has
been widely documented in epidemiological studies. Phenethyl isothiocyanate
(PEITC) occurs as its glucosinolate precursor gluconasturtiin in the
cruciferous vegetable watercress (Nasturtium officinale). PEITC has multiple
biological eﬀects, including activation of cytoprotective pathways, such as
those mediated by the transcription factor nuclear factor erythroid 2
p45-related factor 2 (NRF2) and the transcription factor heat shock factor 1
(HSF1), and can cause changes in the epigenome. However, at high
concentrations, PEITC leads to accumulation of reactive oxygen species and
cytoskeletal changes, resulting in cytotoxicity. Underlying these activities is
the sulfhydryl reactivity of PEITC with cysteine residues in its protein targets.
This chemical reactivity highlights the critical importance of the dose of PEITC
for achieving on-target selectivity, which should be carefully considered in the
design of future clinical trials.
1. Introduction
Glucosinolates (β-thioglucoside N-hydroxysulfates; GS) are
naturally occurring compounds that are precursors for iso-
thiocyanates (ITCs). These phytochemicals are of widespread
occurrence in the cruciferous vegetables, the Cruciferae or Bras-
sicaceae family containing hundreds of genera and thousands
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of species, and about 15 other plant
families.[1] Over the past ﬁve decades
it has been demonstrated in various
preclinical, clinical, and epidemiological
studies that dietary intake of cruciferous
vegetables reduces the risk of cancer. In
addition, many of the ITCs exert protec-
tive eﬀects in neurodegeneration, cardio-
vascular diseases, bacterial infection, and
inﬂammation.
In the plant, the enzyme myrosi-
nase, a thioglucoside glucohydrolase
(E.C. 3.2.1.147), is physically separated
from its substrate glucosinolates, yet
may be present in the same cells and
tissues.[2] When plants containing glu-
cosinolates are subjected to mechanical
disruption, myrosinase comes into
contact with the glucosinolates and,
depending on substrate chemistry, pH,
presence of Fe2+ ions, and presence
of countervailing enzymes such as
epithiospeciﬁer protein, converts them into either ITCs, thio-
cyanates, or nitriles.[3] In animals, the conversion of dietary glu-
cosinolates to ITCs is also carried out by the gastrointestinal
microﬂora.[4]
Nasturtium oﬃcinale (watercress) is a cruciferous vegetable
that is rich in gluconasturtiin, the aromatic glucosinolate pre-
cursor of phenethyl isothiocyanate (PEITC; 2-phenyl ethyl ITC;
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Figure 1. The myrosinase reaction. The glucosinolate gluconasturtiin is hydrolytically cleaved by the enzyme myrosinase to give an unstable aglycone
and liberate glucose. The reaction product spontaneously rearranges into hydrocinnamonitrile and phenethyl isothiocyanate (PEITC).
Figure 2. Cellular processes and pathways that are induced by PEITC (represented by the solid arrows). The dashed arrows represent the downstream
eﬀects/pathways induced as a consequence.
phenyl ethyl ITC; Figure 1).[5] Watercress also contains
smaller quantities of 7-methylsulﬁnylheptyl GS and 8-
methylsulﬁnyloctyl GS.[6] The seeds of the cruciferous Barbarea
verna (land cress) are enriched with only one glucosinolate,
gluconasturtiin, containing approximately 3% by weight.[7]
PEITC is one of the ITCs that have been extensively studied, and
is currently in two clinical trials: for evaluating its safety and ef-
ﬁcacy proﬁle in head and neck cancer patients (NCT03034603),
and for its long-term eﬀects in cancer patients’ outcomes
(NCT02468882; www.clinicaltrials.gov). Due to the presence of
the electron withdrawing ITC (N = C = S) group (Figure 1),
PEITC is highly cysteine reactive and consequently has multiple
intracellular targets. PEITC has been shown to induce the
transcription factor nuclear factor erythroid 2 p45-related factor
2 (NRF2)-mediated cytoprotective pathway and the transcription
factor heat shock factor 1 (HSF1)-regulated heat shock response
(HSR), inhibit phase 1 enzymes, suppress inﬂammation, and
at high concentrations, to cause cell cycle arrest and apoptosis,
alter cytoskeletal structures and the epigenome, and induce the
unfolded protein response (UPR) and autophagy (Figure 2).
The pharmacokinetics and metabolism as well as the chemo-
preventive and chemotherapeutic eﬀects of PEITC have been
comprehensively reviewed.[8] Here, we focus on the ability of
PEITC to induce cytoprotective pathways through activation
of the transcription factors NRF2 and HSF1, and the recently
described epigenetic modiﬁcations caused by this ITC. Finally,
we point out that at high concentrations, PEITC causes accumu-
lation of reactive oxygen species (ROS), leading to cytotoxicity.
2. PEITC Activates the NRF2-Dependent
Cytoprotective Pathway
Oxidation–reduction reactions play a central role in numerous
biological processes. Living organisms are constantly exposed
to ROS (e.g., superoxide anion, hydrogen peroxide, hydroxyl
anion, and singlet oxygen) or reactive nitrogen species (RNS;
e.g., nitroxyl anion, peroxyl nitrate, nitric oxide, and nitrosyl
cation) produced by both endogenous and exogenous sources.
Oxidative stress is deﬁned as the imbalance between oxidants
and antioxidants, where the former are in excess, leading to
disturbances of the intracellular redox homeostasis and subse-
quent damage.[9] Examples of exogenous oxidative stressors are
electrophilic molecules, carcinogens such as DNA-damaging
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agents, heavy metals, and ultraviolet (UV) radiation. Endoge-
nous stressors are usually produced by intracellular metabolic
reactions during processes such as respiration and inﬂam-
mation. Exposure to ROS/RNS or other chemically reactive
species can damage cellular macromolecules such as DNA,
proteins, and cytoskeletal structures. As a consequence, chronic
oxidative stress has been implicated in cancer,[10] diabetes,[11]
neurodegenerative,[12] respiratory,[13] cardiovascular,[13b,14] and
inﬂammatory[15] diseases as well as aging.[16] In order to protect
themselves from such insults, eukaryotic cells have developed
several complex mechanisms to restore cellular redox home-
ostasis. One such mechanism is by inducing the production
of antioxidant and cytoprotective proteins. This cytoprotective
response is orchestrated by the transcription factor NRF2.
At basal conditions, NRF2 is negatively regulated by Kelch-
like (ECH)-associated protein 1 (KEAP1)[17] which functions
as a substrate adaptor protein for Cullin 3–RING (really in-
teresting new gene)-box protein (Rbx) 1-based E3 ubiquitin
ligase, and uses a cyclical mechanism to continuously target
NRF2 for ubiquitination and proteasomal degradation.[18] Small
molecules, including the ITCs sulforaphane (SFN) and PEITC,
which activate NRF2 (termed inducers) block this cycle by
modifying reactive cysteine sensors in KEAP1[19] or disrupt-
ing the KEAP1–NRF2 interaction.[20] Consequently, NRF2 is
not degraded and free KEAP1 is not regenerated. The newly
synthesized NRF2 accumulates, translocates to the nucleus,
and binds (as a heterodimer with a small MAF protein) to
antioxidant response elements (ARE, 5ʹ-TGACnnnGC-3ʹ) in the
upstream regulatory regions of its target genes.[18b–d] In addition
to KEAP1, the activity of NRF2 is also known to be negatively
regulated by glycogen synthase kinase 3 (GSK3)/β-transducin
repeat-containing protein 1 (β-TrCP1)-dependent ubiquitination
and proteasomal degradation,[21] by interaction with retinoid X
receptor (RXR)α,[22] as well as by the ubiquitin ligases synoviolin
(Hrd1)[23] and WDR23-DDB1-Cul4.[24]
NRF2 mediates the transcription of numerous detoxiﬁca-
tion and antioxidant genes. Examples of some of its targets
are NAD(P)H-quinone oxidoreductase 1 (NQO1), glutathione
S-transferases (GSTs), aldo-keto reductases (AKRs), aldose reduc-
tase (AR), γ -glutamyl peptidase (GGT), carboxylesterase (CES),
heme oxygenase 1 (HO-1), UDP-glucuronosyltransferases
(UGTs), thioredoxin (TXN), and glutamate-cysteine ligase
catalytic/modiﬁer subunits (GCLC/GCLM).[18d] In human lym-
phoid cells, using chromatin-immunoprecipitation (ChIP) se-
quencing, Chorley and colleagues identiﬁed 242 high conﬁdence
NRF2 binding sites upon treatment with SFN.[25] The coordinate
upregulation of these NRF2 targets provides the cell with
long-lasting protection against a plethora of damaging insults,[26]
allowing adaptation and survival and restoring homeostasis.
Numerous reports have documented the cytoprotective role
of NRF2 activation by PEITC, and these have been recently
reviewed.[8a–e] Several recent studies after the publication of these
reviews are noteworthy. Through activation of NRF2, PEITC re-
stored insulin-stimulated glucose uptake, translocation of glu-
cose transporter 4, and insulin signaling that were impaired
by treatment of 3T3-L1 adipocytes with hydrogen peroxide,[27]
demonstrating the cytoprotective role of PEITC under condi-
tions of dysregulated glucose metabolism. Dietary administra-
tion of PEITC reduced mucosal and submucosal inﬂammation,
glandular atypia, and tumor development in a mouse model of
colitis-associated colorectal carcinogenesis.[28] PEITC was also
suggested as one potential dietary agent for the prevention and
treatment of malignant mesothelioma.[29] Treatment with PEITC
of neonatal humanizedUDP-glucuronosyltransferase 1 (hUGT1)
mice, which have high levels of serum bilirubin due to a develop-
mental delay in the expression of the NRF2 transcriptional target
UGT1A1, the enzyme that catalyzes the conjugation of bilirubin,
induced UGT1A1 in liver and intestine, and reduced the serum
bilirubin.[30] In addition to upregulating the transcription of cyto-
protective genes, NRF2 downregulates the expression of genes
involved in lipid synthesis, including acetyl-CoA carboxylase 1
(ACC1), fatty acid synthase (FASN), and carnitine palmitoyltrans-
ferase 1 (CPT1),[31] and this downregulation has been proposed
to play a role in the ability of PEITC to prevent prostate cancer
in the transgenic adenocarcinoma of mouse prostate (TRAMP)
model.[32] In human prostate cancer cells, exposure to PEITC in-
duced the appearance of membranous vacuoles and the recruit-
ment of microtubule-associated protein 1 light chain 3 (LC3) to
autophagosomes, promoting autophagy.[33] Interestingly, inhibi-
tion of autophagy enhanced the inhibitory eﬀect of PEITC on the
metastatic potential of lung cancer cells,[34] suggesting that the
PEITC-mediated autophagy plays a cytoprotective role. NRF2 ac-
tivation promotes autophagic ﬂux,[35] but whether or not NRF2
is required for the ability of PEITC to induce autophagy, has not
been examined.
Due to its highly reactive electron withdrawing isothiocyanate
group (Figure 1), PEITC reacts readily with the cysteine of glu-
tathione in a reaction catalyzed by glutathione transferases,[36]
and it has been assumed that the ITC activates NRF2 by mod-
ifying cysteine residue(s) in KEAP1. However, the precise iden-
tity of the cysteine sensor(s) in KEAP1 for PEITC is unknown.
This is an important question in view of the prominent role
of NRF2 as a mediator of the cytoprotective activity of PEITC.
Amongst the 25 (mouse) or 27 (human) cysteines in KEAP1,
C151, C273, and C288 are the best-characterized inducer sensors
(Figure 3). It is established that C151 serves as the main sensor
cysteine in KEAP1 for SFN.[37] To identify the cysteine sensor(s)
for PEITC, we used stable cell lines of KEAP1-knockout mouse
embryonic ﬁbroblast cells (KKO MEF cells) that had been res-
cued with either wild-type (WT) KEAP1 or the KEAP1 mutants
C151S and C151S/C273W/C288E by introduction of an hemag-
glutinin (HA)-tagged KEAP1 expression vector ligated to the Pig-
gyBac transposon system.[38] Importantly, all of these mutants
have been previously designed and validated to retain their abil-
ity to target NRF2 for degradation.[38] Exposure to PEITC caused
stabilization of NRF2 in cells from all genotypes. A closer in-
spection revealed that compared to KKO MEF cells rescued with
the WT KEAP1, NRF2 stabilization following exposure to the
low (2.5 μm) concentration of PEITC was attenuated in the KKO
MEF cells rescued with either the single mutant C151S or the
triple mutant C151S/C273W/C288E KEAP1 (Figure 4A), indicat-
ing that C151 plays a role in the sensing mechanism. However,
exposure to the high (7.5 μm) concentration of PEITC caused the
stabilization of NRF2 to nearly identical levels in all genotypes re-
gardless of the mutation status of KEAP1 (Figure 4A). Curiously,
for reasons that are unclear at this time, at the high concentration
tested, PEITC increased the levels of HA-KEAP1 only in cells ex-
pressing wild type, but not any of the mutants of KEAP1.
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Figure 3. Schematic representation of mouse KEAP1 and human HSP90β. A) KEAP1 is a homodimeric protein which has ﬁve distinct domains: N-
terminal region (NTR), broad complex, Tramtrack, Bric-a´-brac (BTB), intervening region (IVR), Kelch domain (KELCH), and the C-terminal region (CTR).
B) HSP90β has an N-terminal domain (NTD), where ATP binds. The middle domain (MD) allows for client protein binding and the C-terminal part of
the MD together with the C-terminal domain (CTD) allows for homodimerization of the chaperone. Various co-chaperones are able to bind to all three
domains with diﬀerent aﬃnities. Client proteins are also able to interact with each of the HSP90 domains. The black bars represent cysteine residues
present in each of the proteins, and some of the reactive cysteines are indicated.
We had previously generated KEAP1C151S/C151S knock-in mice
using the CRISPR/Cas9 gene editing technology.[38] This model
provided an opportunity to test the importance of C151 in
sensing of PEITC using primary cells from these mice. Primary
peritoneal macrophages can be obtained in high yield and
purity after sterile elicitation with thioglycolate broth[39] and
are very sensitive to NRF2 activation ex vivo.[40] We therefore
used this experimental system to compare NRF2 stabilization
by PEITC (at concentrations ranging from 1 to 7.5 μm) in
primary peritoneal macrophage cells isolated from wild-type and
KEAP1C151S/C151S knock-in mice. In close agreement with the
data in MEF cells, we found that following treatment with the
lowest (1 μm) concentration of PEITC, the stabilization of NRF2
was attenuated in the KEAP1C151S/C151S primary macrophage
cells compared to their wild-type counterparts (Figure 4B). How-
ever, this diﬀerence between the genotypes was lost when the
cells were exposed to higher concentrations of PEITC. Notably,
lower concentrations of PEITC were used for the experiments
with primary macrophage cells than the concentrations used for
MEF cells due to the greater inducer sensitivity of primary cells
compared to established cell lines.
Together, these data strongly suggest that C151 in KEAP1 is
the primary sensor for PEITC, but at high concentrations of the
ITC, this cysteine becomes “saturated,” and other cysteines are
also modiﬁed, ultimately leading to NRF2 stabilization. Notably,
C151 in KEAP1 is particularly highly reactive due to the pres-
ence of ﬁve proximate basic amino acid residues (H129, K131,
R135, K150, and H154),[41] which have the ability to deproto-
nate the sulfhydryl group of the cysteine, thus lowering its pKa.
These data also raise the possibility that, at high inducer concen-
trations, cysteine(s) in other proteins may react with PEITC. It
is interesting to note that the highest concentration of PEITC
(7.5 μm) caused a signiﬁcant reduction in the protein levels of
α-tubulin (Figure 4B). It has been reported that the ITCs benzyl-
ITC (BITC), PEITC, and SFN covalently modify α-tubulin in cells
by reacting with its cysteine residues and as a consequence, pre-
venting its polymerization[42] (also see section 5 below). In addi-
tion, PEITC promotes the degradation of both α- and β-tubulin
in prostate cancer PC3 cells; this degradation could be rescued by
co-incubation with the antioxidant N-acetyl-L-cysteine (NAC).[43]
Together, these results conﬁrm that cysteine reactivity underlies
the multiple biological activities of PEITC.
3. PEITC Activates the HSF1-Dependent Heat
Shock Response
The HSR is a transcriptional program that is elicited by the
transcription factor HSF1 which in normal cells is a cytoprotec-
tive mechanism to ensure adaptation and survival during con-
ditions of stress, including exposure to elevated temperatures
or proteotoxic chemicals, oxidative stress, heat shock protein 90
(HSP90) inhibition, and proteasome inhibition. We have shown
previously that numerous sulfhydryl-reactive NRF2 activators,
are able to activate the HSR through the transcription factor
HSF1, although the concentrations required for HSF1 activa-
tion are higher than those that activate NRF2.[44] Over the past
decade, a number of studies have shed light onto the capacity of
ITCs to induce the HSR. For example, SFN causes nuclear accu-
mulation of HSF1[45] and induces the expression of HSP27 and
HSP70.[45,46] BITC and PEITC have also been reported to induce
the expression of heat shock proteins[47] and reduce the formation
of aggresome-like structures following proteasomal inhibition.[48]
In one proposed mechanism, under basal conditions, the in-
active monomeric HSF1 is primarily sequestered in the cyto-
plasm by the HSP90 multi-chaperone complex.[49] The HSP90
multi-chaperone complex includes co-chaperone proteins p23,
HSP70, HSP40, scaﬀold for HSP90/HSP70 interaction (STIP1),
and cell division cycle 37 (CDC37).[50] HSP90 mediates the fold-
ing and stabilization of its client proteins through its ATPase
cycle, which is mediated by dynamic interactions with its co-
chaperones. Inhibition of HSP90 function by pharmacological
inhibitors can manifest in the following ways: 1) physical bind-
ing to HSP90 itself at its N-terminal ATP binding pocket or at
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Figure 4. C151 in KEAP1 is the primary sensor for PEITC, but is not re-
quired at high inducer concentrations for the stabilization of NRF2. A)
Stable KEAP1-knockout MEF cells rescued with either WT, single mu-
tant C151S, or triple mutant C151S/C273W/C288E of mouse N-terminally
tagged HA-KEAP1 were generated as described.[38] Cells were plated in 6-
well plates at a density of 106 cells per well, and placed in a 37 °C humid-
iﬁed incubator in 5% CO2 in air. On the following day, cells were treated
with vehicle (0.1% DMSO) or the indicated concentrations of PEITC for
3 h. B) The animal experiments were approved by the Tohoku Univer-
sity Animal Care Committee and were compliant with the regulations of
The Standards for Human Care and Use of Laboratory Animals of Tohoku
University (Sendai, Japan) and the Guidelines for Proper Conduct of An-
imal Experiments of the Ministry of Education, Culture, Sports, Science
and Technology of Japan. Wild-type and KEAP1C151S/C151S knock-in mice
were generated, bred, and maintained at Tohoku University. Peritoneal
macrophage production was elicited by i.p. injections of 4% thioglycolate
solution using the previously described method.[38] Four days later, peri-
toneal macrophage cells were extracted, washed, plated in 6-well plates
at a density of 106 cells per well, and placed in a 37 °C humidiﬁed incu-
bator in 5% CO2 in air. Four hours later, when the cells had adhered to
the plates, they were washed twice with phosphate buﬀered saline (PBS)
before proceeding with treatments with vehicle (0.1% DMSO) or the in-
dicated concentrations of PEITC for 3 h. For western blot analysis, cells
were lysed, proteins were separated by electrophoresis on an 8% SDS-
polyacrylamide gel, and electrophoretically transferred to a polyvinylidene
diﬂuoride (PVDF)membrane. After blocking with 10%nonfatmilk at room
temperature for 1 h or overnight at 4 °C, immunoblotting was performed
using the following antibodies for either 1–2 h at room temperature or
overnight at 4 °C: rat monoclonal NRF2 antibody [154] at a dilution of
1:100, rat monoclonal HA antibody (Roche, 3F10, CA, USA, at a dilution
of 1:1000) or rat monoclonal KEAP1 antibody [154] at a dilution of 1:100.
A mouse monoclonal antibody against α-tubulin (Sigma-Aldrich, DM1A,
1:5000–1:10000 dilution) was used as a loading control.
its C-terminus, 2) modiﬁcation of the cysteines which are only
present in its middle domain, 3) physical interaction with its co-
chaperones, and 4) global increase in the levels of unfolded pro-
teins. In all the four circumstances, HSP90 is unable to mediate
its client protein folding and stabilization. HSP90 has more than
200 client proteins.[51] Exposure to stress causes HSF1 to disso-
ciate from the HSP90 multi-chaperone complex, and promotes
its hyperphosphorylation. Subsequently, HSF1 translocates to
the nucleus where it forms transcriptionally active homotrimers
that bind to genomic heat shock element (HSE) sequences (5ʹ-
nTTCnnGAAn-3ʹ) to activate transcription of its diverse target
Table 1. Examples of HSP90 client proteins that are downregulated at the
protein level in response to PEITC categorized by their associated roles.
Function HSP90 Clients
Cell division cycle CDC25,[90] CYCLIN D1,[91]
CYCLIN B1,[92] CDK1,[90,92]
CDK4,[92] CDK6,[92] WEE1[74d]
Apoptosis BCL-2,[80b,92] BCL-xL[80b,81]
Angiogenesis HIF-1α,[93] VEGFR1[94]
Invasion and metastasis MMP2, 9[95]
DNA damage response SP1,3,4,[94] DNMT1, 3A, 3B[66]
Proliferation and
survival
HER2,[56,96] STAT3,[96] RAF1,[56]
EGFR,[96] AKT,[70,97] PDK1[95a]
genes that encode proteins involved in molecular folding and
chaperoning, metabolism, detoxiﬁcation, and cell signaling.[52]
HSF1’s transcriptional activation is attenuated by binding to
HSP90, HSP70, and HSP40, all of which are its transcriptional
targets, forming a negative feedback regulatory loop.[53]
Due to themounting evidence that the ITCs induce heat shock
proteins, we tested a series ofmildly electrophilic SFN analogues,
and found that sulfoxythiocarbamate alkyne (STCA) modiﬁes
cysteines in HSP90 (Figure 3).[54] We also found that such sul-
foxythiocarbamate derivatives, by virtue of their sulfhydryl reac-
tivity, destabilize HSP90 client proteins and induce the HSR.[55]
With this knowledge, we studied the ability of PEITC to in-
hibit HSP90.[56] We found that PEITC causes the dissociation of
HSF1 from HSP90 and the nuclear accumulation of the tran-
scription factor.[56] In cervical cancer HeLa cells stably transfected
with the HSP70.1 promoter fused upstream of the luciferase
gene, PEITC robustly induced the promoter activity in a time-
and dose-dependent manner.[56] HSP70, the prototypic marker
of activation of the HSF1-mediated transcription, was induced
by PEITC and the induction was absent in MEF cells deﬁcient
in HSF1, suggesting that PEITC induced the HSR by activat-
ing HSF1.[56] In agreement with our ﬁndings, PEITC treatment
in murine hepatoma Hepa1c1c7 cells induced the HSP70 gene
expression.[47a] Furthermore, PEITC caused the degradation of
classical HSP90 client proteins human epidermal growth factor
receptor 2 (HER2) and Raf-1 proto-oncogene, serine/threonine
kinase (RAF1) in MDA-MB-231 breast cancer cells.[56] This is
consistent with a number of publications reporting that expo-
sure to PEITC decreases the levels of proteins such as CDC25,
CYCLIN B1, cyclin-dependent kinase 1 (CDK1), as well as
several histone deacetylases (HDACs), DNA methylases (DN-
MTs), and matrix metalloproteinases (MMPs), all of which are
HSP90 client proteins (Table 1). Another HSP90 client protein is
the pleiotropic cytokine macrophage migration inhibitory factor
(MIF), which is often elevated in cancer cells and correlates with
tumor aggressiveness and poor prognosis.[57] Curiously, PEITC
covalently modiﬁes MIF at its N-terminal proline, P2, causing
conformational changes which disrupt its catalytic tautomerase
activity as well as its binding to other proteins.[58]
Phosphorylation of HSF1 at serine 326 (pS326) is one of
the primary and hallmark posttranslational modiﬁcation (PTM)
events that occur during HSF1 activation. Within minutes,
PEITC induced the phosphorylation of HSF1 at S326 as well
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as the activation of the p38 mitogen-activating protein kinases
(MAPKs).[56] By the use of p38 MAPK inhibitors, we found that
the p38 gamma isoform was, in part, responsible for the phos-
phorylation of HSF1 pS326 upon PEITC exposure. A higher con-
centration of PEITC caused a persistent phosphorylation at S326
and activation of theHSR even 24 h after treatment. Inmany can-
cers, HSF1 is activated and it has been shown that HSF1 over-
expression promotes aneuploidy and malignant phenotypes as
cells become addicted to the cytoprotection it confers.[59] Specif-
ically, high HSF1 pS326 levels correlate with poor patient prog-
nosis in several cancers.[60] Cancer cells have elevated HSF1 and
heat shock protein levels due to the increased levels of mutant
proteins, which require stabilization through these chaperoning
machineries. Therefore, in the context of cancer, inhibiting the
“normal” HSP90 function is beneﬁcial; however, the consequent
activation of the HSF1-mediated transcriptional response feeds
these oncogenic protein helpers (i.e., HSP90 and HSP70) into
the same system. Therefore, one of the challenges in targeting
HSP90 in cancer is to ﬁnd compounds that speciﬁcally inhibit
HSP90 without activating the HSR, or to use classical HSP90 in-
hibitors in combination with HSF1 inhibitors.
It is currently not known how PEITC inhibits HSP90, and
several possibilities could be considered. First, similar to STCA,
PEITC may directly modify cysteines in HSP90. Second, PEITC
may modify cysteines in HSP70. By use of [14C]-PEITC and mass
spectrometry, PEITC has been found to bind HSP70, which is
a component of the HSP90 multi-chaperone complex.[61] Third,
PEITC has been reported to induce the UPR[62] and inhibit
the 20S and 26S proteasomal subunits,[63] where both of these
conditions have been shown to induce the HSF1-mediated
HSR.
4. PEITC and Epigenetic Regulation: An Emerging
Field
In the prostate cancer cell line LNCaP, the GSTP1 gene is
silenced due to the aberrant methylation of its promoter. In
these cells, PEITC exposure induced demethylation of the CpG
island of theGSTP1 promoter, and ultimately reactivatedGSTP1
expression.[64] In this study, PEITC was shown to decrease the
activity of HDAC1 and HDAC2, and decrease the expression of
the HDAC1. Also, PEITC promoted the acetylation of histone
H3 (hH3), methylation of hH3 at lysine 4, and the demethylation
of hH3 at lysine 9. Remarkably, the androgen responsive LNCaP
cells when treated with PEITC were able to diﬀerentiate into
prostate cancer stem cells (PCSC) ﬂoating spheres, leading the
researchers to hypothesize the epigenetic alterations exerted by
ITC, decreased expression of DNMT1, increased histone H3K4
acetylation, and reactivated GSTP1 expression in the spheric
PCSCs.[65] Interestingly, PEITC treatment in LNCaP cells causes
the epigenetic reactivation of Ras-association domain family 1
isoform A (RASSF1A) gene by enhancing CpG demethylation
at its promoter. In this study, PEITC also reduced the expression
of the DNMTs 1, 3A, and 4 as well as HDACs 1, 2, 4, and 6.[66]
Additionally, in LPS-stimulated human colon epithelial cells
SW480, PEITC treatment decreased the expression of several
genes (e.g., interleukin 8 [IL-8], MMP7, signal transducer and
activator of transcription 1 [STAT1], and nuclear factor of kappa
light chain gene enhancer in B cells 1, p105 [NF-κB1]) by causing
the trimethylation of hH3 at lysine 27 (H3K27me3).[67] It is yet to
be investigated whether the histone methylase(s) that is involved
in the trimethylation at H3K27me3 is in some way activated by
PEITC treatment.
Recently, Lawson and colleagues found that, possibly through
the modiﬁcation of their cysteines, PEITC targets various deu-
biquitinases (DUBs) many of which (e.g., VCPIP1, USP1, USP3,
USP16, and USP48) are involved in chromatin remodeling and
DNA repair. PEITC also decreases the levels of DUBs by initi-
ating their degradation.[68] Another mechanism by which PEITC
could regulate the epigenome is by altering the expression of
a number of microRNAs (miRNAs).[69] In PC3 cells, PEITC in-
duced the expression of miR-194, which was able to suppress cell
invasiveness in vitro. In the same system, miR-194 induction by
PEITC inhibited the expression of bone morphogenetic protein
1 (BMP1) which in turn attenuated the expression of the onco-
genic MMP2 and MMP9. Suppression of MMP9 expression (by
inhibiting NFκB and AP-1) and reduction of lung metastasis by
PEITC, BITC, and SFN was shown in an A549 xenograft mouse
model.[70] The inhibition of MMP2 activity by PEITC and BITC,
which was accompanied by reduced cell migration and invasion,
was also reported in the human melanoma cell line A375.S2[71]
and in the mouse melanoma cell line B16F10.[72] Both MMP2
andMMP9 are client proteins of HSP90 (Table 1), but whether or
not the inhibitory eﬀect of PEITC could be in part a consequence
of HSP90 inhibition has not been investigated. Most recently,
it was found that in human prostate cancer cells (LNCaP and
PC3), PEITC induced the expression of the epigenetic regulator
SET domain containing lysine methyltransferase 7 (Setd7),
which in turn activated NRF2, providing an epigenetic mecha-
nistic link to enhancing NRF2-dependent cytoprotection by the
ITC.[73]
5. At High Concentrations, PEITC is Cytotoxic
Inhibition of HSP90 and/or glutathione depletion, leading to the
accumulation of ROS, all of which are related to the cysteine re-
activity of PEITC, may provide potential mechanisms for the ob-
servation that, like other ITCs, high concentrations of PEITC are
cytotoxic. PEITC arrests cells at the G2/M phase.[74] In DU145
prostate cancer cells, this cell cycle arrest was mediated by an
increase in p53, and a decrease in CDC25C protein levels.[74]d]
PEITC activation of p53 in oral squamous cell carcinoma cell
lines with a functional p53 caused an induction of the ataxia
telangiectasia mutated serine/threonine kinase-checkpoint ki-
nase 2 (ATM-CHK2) pathway as well as the expression of p21. In-
terestingly, in breast cancer cells expressing mutant p53, PEITC
exposure caused the depletion of mutant p53.[75] Exposure to
PEITC has also been reported to reduce the levels of other cell
cycle regulating proteins such as CYCLIN B1 and CDK1 con-
tributing to the cell cycle arrest at G2/M.[76] Since mutant p53,
CYCLIN B1, and CDK1 are HSP90 client proteins (Table 1), it is
possible that inhibition of HSP90 is an important contributor for
their downregulation upon treatment with PEITC.
Additionally, PEITC induces extrinsic and intrinsic apoptotic
pathways in cancer cells[77] by promoting ROS production,[77c,78]
activating the MAPKs pathways,[79] downregulating the
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anti-apoptotic proteins Bcl-2 and Bcl-x,[80] and activating
the pro-apoptotic proteins Bax and Bak.[81] Exposure to PEITC
causes the activation of stress-activated MAPKs such as c-Jun
N-terminal kinase (JNK),[77a] p38 MAPKs,[56,82] and extracellular
signal-regulated kinase1/2 (ERK1/2).[83] It has been shown by
several groups that the activation of these kinases by PEITC
correlates with activation of the caspase-dependent apoptotic
pathway, and that chemical inhibition of these kinases blocks this
process. For example, chemical inhibition of only JNK activity,
and not p38 MAPK or ERK1/2, in human colon adenocarcinoma
cells (HT-29) reduced PEITC-induced apoptosis.[79a] Inhibition
of the p38 MAPK with the inhibitor SB202190 did not prevent
apoptosis activation by PEITC in PC3 cells; however, treatment
with the ERK1/2 inhibitor, PD98059 achieved this eﬀect.[82] In
another study in human oral cancer cells (HN22), inhibition
of p38 MAPK with the SB203580 p38 MAPK inhibitor blocked
apoptosis mediated by PEITC’s activation of the death receptor 5
(DR5).[84] Furthermore, it has been shown that compared to nor-
mal cells, cancer cells are more sensitive to PEITC-mediated cell
death.[85] The seemingly conﬂicting evidence on the dependence
of apoptosis on PEITC-induced activation of speciﬁc MAPKs
could be attributed to diﬀerences in the cancer cell lines used
in these studies, including their individual MAPK and caspase
status, and apoptotic susceptibility.
Another mechanism by which PEITC may promote cell death
is through its ability to modify cellular cytoskeletal elements. Hu-
man lung cancer cells (A549) treated with radiolabelled PEITC
or SFN exhibited binding of the ITCs to tubulin.[86] ITCs cause
tubulin depolymerization in vitro and in vivo by covalently bind-
ing to its cysteines.[86] Because A549 cells have constitutively ac-
tive NRF2 due to inactivating mutations in KEAP1,[87] this ﬁnd-
ing highlights the importance of sulfhydryl reactivity of the ITCs
in covalently modifying cysteine residues even under conditions
of constitutive NRF2 activation. PEITC also inhibited the expres-
sion of α- and β-tubulin in PC3 cells.[43] Themodiﬁcation and de-
polymerization of tubulin by PEITC might be part of the mech-
anism by which the ITC inhibits cell proliferation and induces
apoptosis and cell cycle arrest. In addition, the covalent modiﬁca-
tion of α- and β-tubulin by PEITC has been shown to induce the
formation of aggresome-like structures.[47e] In the breast cancer
cell lines MCF7 and MDA-MB-231, a 48 h exposure of PEITC-
induced α-tubulin acetylation, possibly through the inhibition of
HDAC6.[88] In the lung cancer cell lines A549 and H1299, in ad-
dition to tubulin degradation, PEITC caused disassembly of actin
stress ﬁbers, accompanied by cytotoxicity, which was less pro-
nounced in A549 cells,[89] in agreement with their constitutively
high NRF2 levels.
6. Conclusion
PEITC has multiple intracellular targets. PEITC activates the cy-
toprotective transcription factors NRF2 and HSF1 and modiﬁes
the epigenome. At high concentrations, PEITC is cytotoxic. Im-
portantly, the ability to react with cysteines has been implicated
in all of the biological activities of PEITC. Hence, the on-target
selectivity of PEITC depends on its concentration. It is thus es-
sential to carefully consider the dose and duration of treatment
when designing future clinical trials.
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